Gene Carriers and Transfection Systems Used in the Recombination of Dendritic Cells for Effective Cancer Immunotherapy

Table 1

Overview of recent studies using Ad vectors for gene transfer in DCs.

Cancer	Transfer molecule	In vitro	In vivo in animal model	Reference
Prostate	tPSMA and 4-1BBL	High IFN-production	Strong antitumor immunity	[83]
	STEAP	High IFN-production	Inhibition of tumor growth, vaccination delaying the growth of pre-established tumors	[84]
Hepatoma	mTERT	High IFN-and IL-2 production	Inhibition of the tumor growth	[85]
	hTERT	Inducing strong CTL response	Inducing anti-tumour immunity	[63]
	HCC and CD40L	Increasing DCs IL-12	Inducing complete regression of established tumors and long-term immunity against tumor recurrence	[86]
	AFP and HBsAg	Inducing CTLs killing HepG2.2.15 cell lines	Inhibition of tumor growth in immunodeficiency mice	[87]
Leukemia	Survivin and GM-CSF	Much higher activity of CTL than DCs with either	No data available	[88]
	IL-12 with tumor cell lysate	No data available	Prolonged survival time	[89]
Metastatic lung cancer	IL-12- and 4-1BBL	High IFN-production and CTLs response	Greater antitumor and antimetastatic effects than either treatment alone higher migratory abilities of DCs	[90]
Lung	livin	Inducing CTLs lysing LLC	Inducing a potent protective and therapeutic antitumor immunity	[91]
Urologic cancer cells	Survivin	Inducing CTLs against various bladder, kidney, and prostate cancer cells	No data available	[92]